Southeast Asia Breast Cancer Market to Post 16.2% CAGR to 2022, States GBI Research in Its Discounted Study Available at MarketPublishers.com
23 May 2017 • by Natalie Aster
LONDON – To date, there are well-entrenched novel targeted products in the breast cancer market in Southeastern Asia; these includes Kadcyla and Perjeta, tyrosine kinase inhibitors (TKIs) such as Tykerb, and CDK inhibitors like Ibrance, among others.
There are close to 1,150 active pipeline molecules. The pipeline includes a set of molecular targets and types, comprising those that are well entrenched in the breast cancer domain, and new, first-in-class therapies.
According to the analysis of clinical studies since 2006, the highest failure rates (59%) of breast cancer molecules were observed in Phase II, with the overall attrition rate for breast cancer therapies amounting to 85%.
The region’s breast cancer market is projected to increase from USD 942.3 million in 2015 to USD 2.7 billion by 2022, posting a 16.2% CAGR.
South Korea is poised to keep on dominating the regional market, owing to the emergence of new therapies and the constant acceptance of branded treatment options.
In most nations in the region, the highest unmet need is in the absence of a defined management program for this disease, low affordability, and patients keeping on placing reliance on the usage of chemotherapies in later-line treatments. Drug manufacturers should consider the developing reimbursement landscape when defining pricing strategies in the markets of Southeastern Asia, because this is likely to greatly influence the use of premium drugs.
Discounted study “Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market” created by GBI Research provides deep, reliable insights into the clinical and commercial universe by considering the disease diagnosis, pathogenesis, prognosis, and the therapies. It analyses the structure of the breast cancer market with respect to dominant therapies, alongside highlighting the unmet needs.
It analyses the disease pipeline and stratifies pipeline therapies based on phase of development, molecule type and target. The report uncovers the potential of late-stage treatment modalities, offering in-depth profiles of products that can potentially come into the market in the offing. It includes detailed market growth forecasts in the 8 Southeast Asian markets, with epidemiological projections and annual cost of treatment forecasts, etc. The research study canvasses the trends in co-development and licensing deals in the breast cancer marketplace.
Note that currently GBI Research provides a special discount offer, the details are available at this page.
More discounted and new reports by this publisher are at hand at GBI Research page.